Emma Aneheim from Alpha Therapy Solutions awarded the Henry Wallman Prize
For the third year in a row, The Foundation for Bio-Medical Engineering will award the Henry Wallman Prize to a medical technology researcher or research group. This year, the foundation is proud to announce that the 2020 prize will be awarded to Associate Professor Emma Aneheim with the motivation:
In her research, Emma Aneheim has developed a technology for targeted radiation therapy against cancer. The technology is based on so-called astatinated antibodies and Emma Aneheim has played a crucial role in developing an automated production platform for astatinated drugs in a reproducible, standardized and GMP-adapted way. The method forms the basis for a biotech company, Alpha Therapy Solutions AB. The company is now marketing a technology giving researchers across the world a tool for clinical trials with astatinated drugs.
Emma Aneheim has a master’s degree in chemical engineering and a PhD in nuclear chemistry from Chalmers University of Technology. She now holds a position at the Department of Radiation Physics, Sahlgrenska Academy, where her sphere of activities includes clinical studies of ovarian cancer treatment using her technology. Emma Aneheim is a good example of what can be achieved when high engineering competence and clinical problems meet in a fruitful collaboration across disciplines.
When will the award ceremony take place?
The prize of 50.000 SEK will be awarded at a ceremony later this year. If you want to be sure not to miss it, please send an email with your name and email address, and we’ll make sure that you get an invitation: (firstname.lastname@example.org).
Who is Henry Wallman?
Professor Henry Wallman was a pioneer in bio-medical engineering research and development. His work in the 1950s laid the foundation for Chalmers University of Technology and also important parts in Swedish research in the field. An important part of Henry Wallman’s deed was his philosophy and vision around close collaboration between technical and medical expertise to achieve success in his work. This approach has since characterized the activities and the people who have directly followed in his tracks at Chalmers – from now deceased Professor Torsten Olsson, via Kaj Lindecrantz, Bengt Arne Sjöqvist, Mikael Persson and Bo Håkansson, until today’s researchers and Ph.D. students.
Alpha Therapy Solutions is a portfolio company to Chalmers Ventures